Novartis's remibrutinib has met the primary endpoint in both replicate Phase III trials in relapsing multiple sclerosis (RMS), demonstrating superiority over Sanofi's Aubagio (teriflunomide) in reducing annualized relapse rate (ARR) and on all key secondary endpoints, including MRI lesion burden. Novartis said it plans to submit to health authorities globally.
The REMODEL-1 and REMODEL-2 trials each enrolled approximately 1,000 adults with RMS and evidence of recent disease activity, randomizing them 1:1 to remibrutinib 100 mg or teriflunomide in a double-blind, active comparator-controlled design. Both studies met their primary ARR endpoint, and a preplanned combined analysis showed a positive trend on 3-month confirmed disability progression (3mCDP) and nominal significance on 6-month confirmed disability progression (6mCDP). Specific ARR values, hazard ratios, and p-values were not disclosed in the topline release; full data will be presented as a late-breaker at MSToronto2026. The safety profile was consistent with remibrutinib's broader clinical program across more than 4,500 participants, with no liver safety signal and no cases meeting Hy's Law criteria — a point of differentiation from earlier-generation BTK inhibitors that carried hepatotoxicity concerns.
Remibrutinib covalently inhibits Bruton's tyrosine kinase (BTK), blocking downstream B-cell receptor signaling and reducing activation of both peripheral B cells and innate immune cells, including CNS-resident microglia — offering a potential way to modulate compartmentalized neuroinflammation that is less directly targeted by peripheral B-cell-depleting antibodies.
The RMS treatment landscape is dominated by high-efficacy anti-CD20 agents — Roche's Ocrevus (ocrelizumab) and Novartis's own Kesimpta (ofatumumab) — administered by infusion or injection. The oral high-efficacy segment is less crowded: cladribine requires only short annual courses but operates via immune reconstitution rather than continuous suppression, while sphingosine-1-phosphate receptor modulators such as Johnson & Johnson's Ponvory (ponesimod) — which demonstrated superiority over teriflunomide in the OPTIMUM trial — carry cardiac monitoring requirements. Remibrutinib's oral twice-daily format, absence of required laboratory monitoring in its approved CSU indication, and clean hepatic safety profile across a large development program differentiate it from both classes. The REMODEL trials used teriflunomide as comparator rather than a high-efficacy agent, so the magnitude of remibrutinib's advantage over anti-CD20 therapies remains to be established in direct comparison.